DermaSensor

12/23/2025

💫 Worth the read: Cody Simmons’ latest Forbes article on the future of skin cancer diagnostics!

Early detection still depends heavily on clinician experience and visual inspection by specialists. But with dermatologist shortages and long referral delays, primary care physicians are increasingly on the front lines of skin cancer detection, often without the tools, training, or time needed to assess suspicious lesions with confidence and accuracy.

In this Forbes Business Council article, Cody Simmons unpacks what that means for the future of skin cancer detection. He shares a measured, evidence-based view on how AI can support clinical confidence and accuracy, without replacing clinical judgment.

👇 Read the full article - https://hubs.li/Q03YZzKq0

As the diagnostic landscape evolves, several patterns are emerging across both clinical research and market innovation.

12/16/2025

A quick assessment. Five gentle recordings. Instant clarity.

See how DermaSensor is transforming skin cancer assessments.

🎥 Watch our Associate Director of Medical Affairs demonstrate how this handheld device uses light-based technology and real-time AI analysis to evaluate suspicious skin lesions in seconds.

With:
✔️ 97% of Monitor results found benign
✔️ 96% sensitivity for detecting skin cancer

…clinicians gain valuable support right at the point of care.

👉 Tap to watch DermaSensor in action.

12/10/2025

Skin cancer affects 1 in 5 Americans — and early detection saves lives.

When melanoma is found early, survival rates exceed 99%.

DermaSensor gives primary care teams a fast, non-invasive way to assess suspicious skin lesions right in the exam room — with objective results in seconds.

✨ Clinical Highlights:
• 96% sensitivity in a large, multi-center study
• Helped reduce missed skin cancers by half
• Consistent performance across all skin tones

Empowering clinicians with better tools means more patients get the early answers they need.

👉 Explore the clinical evidence behind DermaSensor: https://www.dermasensor.com/resources/filter/content/brochures-clinical-evidence/

12/05/2025

FDA-Cleared AI Skin Cancer Detection for Primary Care — 90 Days Risk-Free

Join primary care practices nationwide detecting skin cancer with 96% sensitivity.

DermaSensor delivers confident diagnoses with:

- Handheld, point-and-click application
- Non-invasive optical spectroscopy
- Cellular-level analysis beneath the skin

Year-End Special:
✓ 90-Day Risk-Free Trial
✓ $0 Setup or Hardware Fees
✓ Free Billing & Reimbursement Guidance

Start 2026 with more confident, AI-supported skin cancer detection at the point of care.

👉 Request a Demo: https://www.dermasensor.com/requestdemo/

For healthcare professionals only.

12/03/2025

We’re honored to announce that DermaSensor has been selected by Inc. Magazine for the 2025 Awards in the Best in Innovation category.

This recognition celebrates companies making a meaningful impact through innovation, ex*****on, and industry leadership — from product breakthroughs to measurable outcomes for customers and communities. Being selected alongside forward-thinking companies such as NVIDIA, AlphaSense, Logitech, Alafair Biosciences, Anthropic, and others, inspires us to keep pushing the boundaries of what’s possible.

At DermaSensor, our team remains focused on advancing early detection of skin cancer in primary care, and this honor highlights the integrity, vision, and ex*****on that drive our mission forward.

Thank you, Inc. Magazine., for this recognition — and congratulations to all fellow honorees shaping the future of business.

12/02/2025

Boston University recently spotlighted the early photonics research that helped shape the technology behind the DermaSensor device.

In the video, Professor Irving Bigio shares how this light-based innovation began in the lab and is now supporting skin-lesion assessments in primary care.

Curious how this technology is being used today?
Learn more or book a demo: https://hubs.li/Q03WwzYC0

11/24/2025

The landscape of AI in healthcare is evolving rapidly; however, many tools are still reaching patients without clinical trials or FDA oversight. A recent article from the Duke University School of Medicine, titled “Current Landscape of AI Regulation in Dermatology,” published in JAAD last week, underscores the necessity of strong regulatory standards.

DermaSensor is one of the few AI dermatology technologies that has received FDA De Novo authorization, supported by a clinical trial involving over 1,000 patients, which demonstrated 96% sensitivity. Importantly, DermaSensor’s algorithm is a locked model, meaning that the version cleared by the FDA is precisely what primary care physicians utilize in their practice.

We agree with the article's viewpoint: both initial authorizations and any future updates to the algorithm must undergo appropriate FDA review to ensure patient safety and promote responsible AI innovation in healthcare.

👉 Read the full article here: https://hubs.li/Q03Vtp2M0

11/12/2025

Technology is transforming how primary care physicians evaluate skin cancer risk. 💡

Dr. Bret Kueber shares how DermaSensor allows him to quickly assess suspicious lesions during routine exams — with no disruption to workflow and immediate results that patients appreciate.

Simple. Non-invasive. Backed by AI.

👇 Watch Dr. Kueber’s experience and hear why he recommends DermaSensor.

11/05/2025

Two newly published studies in JAAD International and JCAD validate the consistent performance of DermaSensor’s FDA cleared, AI-powered device and its ability to improve physicians’ melanoma detection. The studies found:

- Melanoma detection increased from 70.2% to 79.1%, decreasing missed melanoma from 29.8% to 20.9%.
- 91.5% of the study physicians agreed the device added value to their clinical care.
- 75% agreed it would help detect more skin cancers.
- 71% reported increased confidence in evaluating skin lesions.

Now in use by hundreds of physicians, DermaSensor continues to empower clinicians with rapid, objective lesion assessments — helping bridge gaps in dermatology access and improve patient outcomes.

📄 Read the full press release: https://hubs.li/Q03RVxQj0

10/29/2025

Every year, millions of Americans are diagnosed with skin cancer - but most cases can be prevented or treated when caught early.

DermaSensor helps physicians non-invasively assess suspicious skin lesions during routine visits, so patients get the reassurance or next steps they need right away.

💙 Find a DermaSensor provider near you: https://hubs.li/Q03QQt_d0

10/23/2025

🏆 DermaSensor has been named “Best in Class – Clinical Diagnostic Device” at the 2025 Digital Health Hub Awards at ! This recognition celebrates real-world innovation in healthcare and we’re proud to empower primary care with real-time, non-invasive skin cancer detection.

From AI-driven breakthroughs to digital health pioneers, we’re honored to stand alongside inspiring leaders shaping the future of care.

10/17/2025

Evaluating suspicious skin lesions remains a challenge — visual exams are subjective, and dermatology training varies widely among clinicians.

DermaSensor is addressing this challenge with its FDA-cleared, AI-powered spectroscopy device that provides fast, objective insights to assess skin cancer risk and support clinical decision-making in real time.

👉 Learn how DermaSensor is advising skin cancer detection https://hubs.li/Q03P5M9f0